The Escalator: MM+M, Dyne Therapeutics, EyePoint Pharmaceuticals and more
New hires:
Dyne Therapeutics hired Doug Kerr, MD, Ph.D., MBA as chief medical officer, Johanna Friedl-Naderer as chief commercial officer and Lucia Celona as chief human resources officer.
Stoke Therapeutics appointed Eric Olson as chief business officer.
Clinical research organizationâ¯Parexel named Mike D’Ambrosio as SVP of real world evidence operations.
Brown Rudnick bolstered its life sciences and technology teams with the addition of partners Vince Shier and Ryan Smith
Calcium+Company, a 2024 MM+M Agency 100 honoree, hired Corina Kellam as its chief marketing and innovation officer.
Flatiron Health hired Quincy Weatherspoon as VP and general manager for the point of care business.
Belite Bio appointed Hendrik P. N. Scholl, MD, MA, as chief medical officer.
Alex Davies stepped down as managing director of Hanover Healthto take up a new role as director of public affairs, medical devices, Europe, at Abbott Laboratories.
SFA Therapeutics appointed Dr. Ananda Gubbi, PhD as director of biostatistics.
Enzene Biosciences hired Norm Stoffregen as SVP and head of biologics manufacturing at its new $50 million biomanufacturing facility in Hopewell, New Jersey.
Scholar Rock tabbed Beth Shafer, PhD as chief business officer.
Healthcare strategic communications consultancy Jarrard expanded its team with six new consultants.
Rectify Pharmaceuticals added Pol Boudes as chief medical officer.
Imre, a 2024 MM+M Agency 100 honoree, appointed Ben Bromberg as EVP of media, as well as Brett Courtright, PharmD, BCPS, AAHIVP as EVP of medical.
Innovation hub Corundum Systems Biology named Jessica Schneider, PhD as chief scientific officer.
The Wake Forest Institute for Regenerative Medicine hired Tim Bertram, PhD as CEO.
Experity hired Saji Rajasekharan as chief technology officer.
Skye Bioscience named Puneet S. Arora, MD, MS, FACE, as chief medical officer.
ReAlta Life Sciences named Peter Ho, PhD as head of business development and corporate strategy.
MM+M hired Jameson Fleming as its next editor-in-chief.
Executive elevations:
LakeShore Biopharma appointed COO Xu Wang as CEO. He succeeds Dave Chenn and Hui Shao, who are stepping down as the company’s interim CEO and co-CEO, respectively.
Medtech service provider RQM+ promoted Ronnie Mahofski and Kevin Rowland to EVP and general manager.
Harness Therapeutics recruited Dr Paulo Fontoura to join its board as non-executive director.
Board appointments:
EyePoint Pharmaceuticals tapped Fred Hassan to join its board of directors.
Atara Biotherapeutics announced the appointment of Gregory A. Ciongoli to its board of directors.
Stephanie Trunzo, SVP and GM of Oracle Industries joined the board of directors at storytelling and technology company Merge.
Gate Bioscience named Jeff Hatfield to its board of directors.
Milestone Pharmaceuticals added Joseph Papa to its board of directors.
Context Therapeutics tapped Dr. Karen Smith and Dr. Luke Walker to join its board of directors.
Departures:
Dyne Therapeutics announced chief medical officer Wildon Farwell, MD, MPH is stepping down from his role and will remain at Dyne full-time through the end of 2024.
Alison Barkoff, the senior official performing the duties of the Administration for Community Living Administrator and Assistant Secretary for Aging, announced that she will be leaving the Department of Health and Human Services in early October.
Dr. Laurie H. Glimcher, CEO of the Dana-Farber Cancer Institute, said she would step down next month.
Immunocore announced CFO Brian Di Donato plans to step down by the end of the year.
Miscellaneous:
Usha Lee McFarling, national science correspondent at STAT News, was selected to receive the 2024 Victor Cohn Prize for Excellence in Medical Science Reporting.
House Oversight Chair Rep. James Comer, (R-KY), told the CEOs of the three major PBMs — CVS Caremark, Express Scripts and Optum Rx — to correct their respective testimonies from a hearing in July.
